drugset
drugset / Trial / NCT01621191

An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)

NCT01621191 ↗

Phase 3 Completed 149 enrolled Eli Lilly and Company Shionogi · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.

Timeline

Start
2012-06
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral

Indications

fibromyalgia